Pathstone Family Office’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Pathstone Family Office’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000	Closed	-$1K	–	1484
2020 Q4	$1K	Hold	1,000	–	–	﹤0.01%	1135
2020 Q3	$2K	Hold	1,000	–	–	﹤0.01%	715
2020 Q2	$4K	Hold	1,000	–	–	﹤0.01%	590
2020 Q1	$4K	Buy	+1,000	New	+$3.29K	﹤0.01%	651

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Pathstone Family Office's BMY.RT Position: Q1 2021 in Review

Pathstone Family Office sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,000 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $4K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Pathstone Family Office reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 1,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
Pathstone Family Office first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
Pathstone Family Office's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4K in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.